ALTEOGEN company profile

196170 · KRX · KRW

Compare ALTEOGEN
₩168,700.00Change from previous close: −2.49%Absolute change: −₩4,300.00

Close · November 18, 2026

Company profile

ALTEOGEN has 181 employees and is headquartered in Daejeon, South Korea.

ALT-P1, a long-acting human growth hormone in a Phase IIa trial, and ALT-Q2, a coagulation factor VII product for hemophilia, anchor the development pipeline of ALTEOGEN Inc. Its oncology candidates include ALT-P7, a targeted drug for breast and gastric cancer in Phase I, and ALT-Q5, an antibody-drug conjugate for ovarian cancer built on its NexMab ADC technology. The company also develops ALT-LS2, a subcutaneous form of trastuzumab for breast and gastric cancer, and works with Kissei Pharmaceutical on ALT-L9, a biosimilar of Eylea, with Cristalia on ALT-L2, a biosimilar of Herceptin, and with Biogen Inc. on subcutaneous formulations of biologics using ALT-B4.

In the fiscal year ended December 2025, revenue reached 215.9 billion won and net income 141.7 billion won. The company, founded in 2008, employs 181 people and is headquartered in Daejeon, South Korea.

Company facts

Industry
Biotechnology
Headquarters
62, Yuseong-daero, 34054, Daejeon
Employees
181
Chief executive
Soon-Jae Park
Founded
2008
Fiscal year
January - December
Listing
196170 · KRX
Currency
KRW
ISIN
KR7196170005

ALTEOGEN and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
ALTEOGEN196170South Korea$9.17B18147.2%97.1
Genscript Biotech1548Hong Kong SAR China$8.83B6,13514.9%—
Haisco Pharmaceutical Group002653China$9.79B5,59721.1%50.6
Akeso9926Hong Kong SAR China$7.6B4,082-30.7%—
Pharmaron Beijing300759China$11.45B25,08814.0%42.4
Sino Biopharmaceutical1177Hong Kong SAR China$12.49B22,83828.2%36.7

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare ALTEOGEN with its competitors